This article only represents the author's own views.
The WuXi PharmaTech family of publicly listed companies, emerging as global leaders in outsourced contract services for drug developers, is about to gain a new member.
That latest addition comes from the antibody-drug conjugate (ADC) space that is fast emerging as a major new hot spot following the big success for PD-1 antibodies. Both traditional drug giants and biopharma startups are piling into the space, boosting demand for outsourced services from contract research, development and manufacturing organizations (CRDMO) with ADC expertise.
您已閱讀8%（598字），剩余92%（6570字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。